- Home
- ATCH vs LIXT Comparison
ATCH vs LIXT Comparison
Compare ATCH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- LIXT
- Stock Information
- Founded
- ATCH 2022
- LIXT 2005
- Country
- ATCH United States
- LIXT United States
- Employees
- ATCH N/A
- LIXT N/A
- Industry
- ATCH
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- LIXT Health Care
- Exchange
- ATCH Nasdaq
- LIXT Nasdaq
- Market Cap
- ATCH 3.0M
- LIXT 2.2M
- IPO Year
- ATCH N/A
- LIXT N/A
- Fundamental
- Price
- ATCH $0.19
- LIXT $0.72
- Analyst Decision
- ATCH
- LIXT
- Analyst Count
- ATCH 0
- LIXT 0
- Target Price
- ATCH N/A
- LIXT N/A
- AVG Volume (30 Days)
- ATCH 2.6M
- LIXT 82.9K
- Earning Date
- ATCH 05-16-2025
- LIXT 08-07-2025
- Dividend Yield
- ATCH N/A
- LIXT N/A
- EPS Growth
- ATCH N/A
- LIXT N/A
- EPS
- ATCH 2.67
- LIXT N/A
- Revenue
- ATCH N/A
- LIXT N/A
- Revenue This Year
- ATCH N/A
- LIXT N/A
- Revenue Next Year
- ATCH N/A
- LIXT N/A
- P/E Ratio
- ATCH $0.07
- LIXT N/A
- Revenue Growth
- ATCH N/A
- LIXT N/A
- 52 Week Low
- ATCH $0.18
- LIXT $0.64
- 52 Week High
- ATCH $66.00
- LIXT $3.00
- Technical
- Relative Strength Index (RSI)
- ATCH 34.16
- LIXT 30.79
- Support Level
- ATCH $0.18
- LIXT $0.64
- Resistance Level
- ATCH $0.20
- LIXT $0.93
- Average True Range (ATR)
- ATCH 0.02
- LIXT 0.13
- MACD
- ATCH 0.01
- LIXT -0.05
- Stochastic Oscillator
- ATCH 10.53
- LIXT 16.99
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.